Cover Image
市場調查報告書

Neuron Biopharma, S.A.:產品平台分析

Neuron Biopharma SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 318939
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Neuron Biopharma, S.A.:產品平台分析 Neuron Biopharma SA - Product Pipeline Review - 2015
出版日期: 2015年11月18日 內容資訊: 英文 25 Pages
簡介

Neuron Biopharma, S.A. 是致力於開發各種神經退化性疾病的預防及治療藥的製藥公司,正在研發及評估治療老年癡呆症用營養補助食品及治療藥。該公司同時也提供低脂血病與神經保護劑及分子方面的服務、研究神經保護用之生物學工具,還有研究中樞神經系統用的新技術。此外也從事大腦方面膽固醇控制的影響相關研究。

本報告提供Neuron Biopharma, S.A.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Neuron Biopharma SA的基本資料

  • Neuron Biopharma SA概要
  • 主要資訊
  • 企業資料

Neuron Biopharma SA:R&D概要

  • 主要的治療範圍

Neuron Biopharma SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Neuron Biopharma SA:開發中產品概況

  • 初期階段有的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Neuron Biopharma SA:藥物簡介

  • NPS-0155
  • NSP-0163
  • NST-0003
  • NST-0004
  • NST-0005
  • NST-0037
  • NST-0060
  • NST-0076
  • NST-0078

Neuron Biopharma SA:開發平台分析

  • 按標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Neuron Biopharma SA:最近的開發平台趨勢

Neuron Biopharma SA:暫停中的計劃

Neuron Biopharma SA:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07703CDB

Summary

Global Markets Direct's, 'Neuron Biopharma SA - Product Pipeline Review - 2015', provides an overview of the Neuron Biopharma SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Neuron Biopharma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Neuron Biopharma SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Neuron Biopharma SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Neuron Biopharma SA's pipeline products

Reasons to buy

  • Evaluate Neuron Biopharma SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Neuron Biopharma SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Neuron Biopharma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Neuron Biopharma SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neuron Biopharma SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Neuron Biopharma SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Neuron Biopharma SA Snapshot
    • Neuron Biopharma SA Overview
    • Key Information
    • Key Facts
  • Neuron Biopharma SA - Research and Development Overview
    • Key Therapeutic Areas
  • Neuron Biopharma SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Neuron Biopharma SA - Pipeline Products Glance
    • Neuron Biopharma SA - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Neuron Biopharma SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Neuron Biopharma SA - Drug Profiles
    • simvastatin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPS-0158
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NSP-0163
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NST-0037
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NST-0076
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NST-0078
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neuron Biopharma SA - Pipeline Analysis
    • Neuron Biopharma SA - Pipeline Products by Target
    • Neuron Biopharma SA - Pipeline Products by Route of Administration
    • Neuron Biopharma SA - Pipeline Products by Molecule Type
    • Neuron Biopharma SA - Pipeline Products by Mechanism of Action
  • Neuron Biopharma SA - Recent Pipeline Updates
  • Neuron Biopharma SA - Dormant Projects
  • Neuron Biopharma SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Neuron Biopharma SA, Key Information
  • Neuron Biopharma SA, Key Facts
  • Neuron Biopharma SA - Pipeline by Indication, 2015
  • Neuron Biopharma SA - Pipeline by Stage of Development, 2015
  • Neuron Biopharma SA - Monotherapy Products in Pipeline, 2015
  • Neuron Biopharma SA - Phase I, 2015
  • Neuron Biopharma SA - Preclinical, 2015
  • Neuron Biopharma SA - Pipeline by Target, 2015
  • Neuron Biopharma SA - Pipeline by Route of Administration, 2015
  • Neuron Biopharma SA - Pipeline by Molecule Type, 2015
  • Neuron Biopharma SA - Pipeline Products by Mechanism of Action, 2015
  • Neuron Biopharma SA - Recent Pipeline Updates, 2015
  • Neuron Biopharma SA - Dormant Developmental Projects,2015
  • Neuron Biopharma SA, Subsidiaries

List of Figures

  • Neuron Biopharma SA - Pipeline by Top 10 Indication, 2015
  • Neuron Biopharma SA - Pipeline by Stage of Development, 2015
  • Neuron Biopharma SA - Monotherapy Products in Pipeline, 2015
  • Neuron Biopharma SA - Pipeline by Top 10 Target, 2015
  • Neuron Biopharma SA - Pipeline by Top 10 Molecule Type, 2015
  • Neuron Biopharma SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top